Drugs.com - New Drug Approvals

FDA Approves Starjemza (ustekinumab-hmny), a Biosimilar to Stelara

Guangzhou and London – May 27, 2025 – Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly...

May 28, 2025 - 00:10
 0
FDA Approves Starjemza (ustekinumab-hmny), a Biosimilar to Stelara
Guangzhou and London – May 27, 2025 – Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly...
Read More

Tags:

Previous Article

US Food and Drug Administration (FDA) Grants Interchangeability Designation to S...

Next Article

Navy relieves senior officer overseeing unmanned, small combatant acquisitions

Related Posts

FDA Approves Bomyntra (denosumab-bnht), a Biosimilar to...

May 12, 2025  0

FDA Approves Brekiya (dihydroergotamine mesylate) Injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

FDA Approves Brekiya (dihydroergotamine mesylate) Injec...

May 26, 2025  0

U.S. FDA Grants Approval for Jivi (Antihemophilic Factor (Recombinant), PEGylated-aucl) in Pediatric Patients 7 to Under 12 Years of Age With Hemophilia A

U.S. FDA Grants Approval for Jivi (Antihemophilic Facto...

May 23, 2025  0